The Company announced its fourth quarter and full year 2017 financial results.
The Company plans on attending the Cowen Health Care Conference on Wednesday, March 14 at 10:40 a.m. ET in Boston and the Barclays Global Healthcare Conference on Thursday, March 15 in Miami.
The Company will host an investor day in New York on November 12, 2015. The event will focus on the Company’s R&D pipeline, commercialization of products and financial outlook.
The Company today announced a $40 million senior secured credit facility with Pacific Western Bank, as agent and lender, and Oxford Finance LLC, as lender.
The Company provided an overview of advances for dogs in osteoarthritis and post-operative pain management at the 2015 International Veterinary Emergency & Critical Care Symposium (IVECCS) in Washington, D.C. on September 18-22.
The Company provided several product updates, including that it continues to advance its deep pipeline of novel therapeutics.
The Company announced that the Board of Directors has elected Wendy Yarno as Chairman of Aratana’s Board of Directors.
The Company announced today its second quarter 2015 financial results and product updates
The Company announced that its strategic partner VetStem Biopharma, Inc. has shared positive results from a dose confirmation study of AT-016, an adipose-derived allogeneic stem cell product exclusively licensed to Aratana for the treatment of osteoarthritis pain in dogs.
The Company today announced the positive results of a pilot field study of AT-002 in cats.
The Company today provided an update on the development, manufacturing and commercialization of their monoclonal antibodies (MAbs) targeting canine B-cell lymphoma (AT-004) and canine T-cell lymphoma (AT-005).
The Company will host a conference call and live audio webcast on Friday, August 7, 2015, at 8:30 a.m. ET, to discuss its financial results for the second quarter ended June 30, 2015.
The Company today announced positive results from its pivotal field effectiveness study of AT-003, the company’s innovative drug for treating post-surgical pain in dogs.
The Company announced positive results from its pivotal field effectiveness study of a therapeutic for appetite stimulation in dogs.
The Company today announced positive results from its pivotal field effectiveness study of AT-002, the company’s innovative therapeutic for appetite stimulation in dogs.
The Company shared findings from the company’s ongoing development programs at the 2015 American College of Veterinary Internal Medicine (ACVIM) Forum.
The Company today announced that it will participate in the William Blair 35th Annual Growth Stock Conference on Tuesday, June 9, 2015 and the JMP Securities Life Sciences Conference 2015 on Tuesday, June 23, 2015.
On May 19, Aratana Therapeutics Founder, President and CEO Steven St. Peter appeared on Fox Business’ “Opening Bell with Maria Bartiromo.”